First AD

Second AD

Panelists share practical tips for colleagues on the use of Janus kinase (JAK) inhibitors in clinical practice and provide final insights on the overall management and treatment of alopecia.

Future Directions in the Treatment of Alopecia Areata

Video content above is prompted by the following:

What kind of tips can you offer colleagues regarding the use of JAK inhibitors in practice?

Please share final thoughts about treatment of alopecia before we conclude today’s discussion.

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

JAK inhibitors have emerged as a promising therapeutic option in the management of alopecia, offering targeted treatment by modulating immune pathways. Clinicians should consider patient-specific factors, such as disease severity and comorbidities, when selecting JAK inhibitors. Monitoring for potential side effects, including infections and hematologic abnormalities, is crucial. Collaboration with dermatologists can enhance treatment outcomes. As the understanding of JAK inhibitors evolves, staying informed about emerging data and guidelines will be essential for optimizing patient care in alopecia management.

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

JAK Inhibitor Baricitinib for Treatment of Alopecia Areata